Q4 report points to progress in the clinic for Gabather

Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002.

Going forward the company will focus on studying the effects of its top candidate on brain activity, which will be a key step in determining dosage of GT-002 to use in future patient studies.